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Dr Senoo has a broad background in arrhythmia, with specific training and expertise in key
researchareas foratrial fibrillation (AF).Asanelectrophysiology fellowat theTheSakakibara
Heart Institute of Okayama in Japan, Dr Senoo first developed his interest into AF and its




Dr Lane is a Senior Lecturer in Cardiovascular Health at theUniversity of Birmingham and is
basedinabusyinnercityteachinghospital.Themainfocusofherrecentworkhasbeenatrial






Professor Lip is Professor of CardiovascularMedicine at the University of Birmingham and is
based inabusycitycentre teachinghospital. ProfessorLiphashadamajor interest into the
epidemiology of AF, as well as the pathophysiology of thromboembolism in this arrhythmia.
Furthermore, hehasbeen researching stroke andbleeding risk factors, and improvements in
clinical risk stratification. The CHA2DS2VASc and HASBLED scores  for assessing stroke and







The availability of four nonVitamin K oral anticoagulants (NOACs), that is, dabigatran,
rivaroxaban, apixaban and edoxaban, have changed the landscape of stroke prevention in
patients with atrial fibrillation. This review article provides an overview of the four phase III
studiesthathavecomparedtheseNOACs,examiningmajoroutcomesofefficacyandsafety.A
range of practical questions relating to the NOACs have emerged, including topics such as
patient selection, treating patients with renal impairment, treating elderly patients, and
combining anticoagulant therapy with antiplatelet drugs.We also address the interaction of













Atrial fibrillation (AF) is a common cardiac arrhythmia and a major cause of morbidity and
mortalityinclinicalpractice.AFincreasestheriskofstroke5foldandisresponsibleforatleast











leading to underuse of VKAs despite the focus of older guidelines on identifying ‘high risk’
patientswhoshouldbetargetedforVKAtherapy.10

In the last decade, several nonVKA oral anticoagulants (NOACs) have emerged as potential
alternatives toVKAs for thepreventionof ischemic strokeand systemicembolism inpatients
withAF.NOACspreviouslyreferredto ‘novel’or ‘new’oralanticoagulants,butmorerecently,
theterminologybecamemoreconfusingwithEuropeansreferringto‘directoralanticoagulants






The four NOACs, which include the oral direct thrombin inhibitor, dabigatran, and the oral
FactorXa inhibitors, rivaroxaban,apixabanandedoxaban,havepredictablepharmacokinetics,







efficacy and safety. A range of practical questions relating to the NOACs have emerged,












results across PROBE and double blind studies and outcomes, and found that amongst
VKAcontrolsubjects,eventratesforstrokeorsystemicembolisminPROBEtrialsat1.74%/year
(95% confidence interval: 1.541.95) was not significantly different from that in doubleblind
trials, at 1.88 (1.732.03). Among other outcomes, O’Neil et al20 also observed VKAtreated




There are important differences in clinical pharmacology among the four NOACs, with
significantimplicationsfortheirclinicaluse(Table1).Rivaroxaban,apixaban,andedoxabanare





substrates of the Pglycoprotein (Pgp) transporter. Dabigatran is excreted unmetabolized by















safety endpoint for all trials, except ROCKETAF, was major bleeding defined according to
InternationalSocietyonThrombosisandHaemostasis(ISTH)criteria,whereasinROCKETAF,the
primary safety endpoint was the composite of “major and nonmajor clinically relevant




studywereathigher riskof stroke (meanCHADS2score=3.5),wereolder,andhadaprevious
strokeorsystemicembolismin>50%ofcases.ThestrokeriskoftheRELYandARISTOTLEtrials
were broadly similar (mean CHADS2 score 2.1) whilst the stroke risk in ENGAGEAF was
intermediate (mean CHADS2 score 2.8) between RELY/ARISTOTLE and ROCKETAF. Table 3














(1.11%vs.1.71%peryear,P<0.001 for superiority)andwasassociatedwitha similar rateof
major bleeding (3.32% vs. 3.57% per year, P = 0.31). Both ischemic and hemorrhagic stroke




systemic embolism (1.54% vs. 1.71% per year, P< 0.001 for noninferiority, P = 0.30 for
superiority) andwas superiorwith respect to the primary safety outcome ofmajor bleeding
(2.87%vs.3.57%peryear,P=0.003).Ischemicstrokewassimilarbetweenthedabigatran110
mg dose group and warfarin (1.34% vs. 1.21% per year, P = 0.35), and hemorrhagic stroke
occurredlessfrequentlyinthedabigatran110mggroup(0.12%vs.0.38%peryear,P<0.001).
Intracranialbleedingoccurredlessfrequentlyinthedabigatrangroups(dabigatran150mgbid







incidenceof strokeand thromboembolismbutwas similar in the incidenceofmajorbleeding




ROCKETAF16 was a randomized, doubleblind, doubledummy, phase III trial of stroke
orsystemic embolism prevention in patients with nonvalvular AF. A total of 14,264 patients
were randomized to receiveeither rivaroxaban20mgoncedaily (od) (15mgod if creatinine
clearancewas30–49mL/min)ordoseadjustedwarfarin(INR2.0–3.0). Inclusioncriteriainthe
studyweredocumentednonvalvularAFoccurringwithinsixmonthspriortorandomizationand
a history of previous stroke, transient ischemic attack (TIA) or systemicembolism, or 2
additional risk factors forstroke:heart failureor leftventricularejection fraction (LVEF)35%,
hypertension,age75years,anddiabetesmellitus.

Rivaroxaban was noninferior to warfarin in the primary endpoint of stroke or systemic
embolismwithanannualrateof2.12%vs.2.42%,respectively(P<0.001fornoninferiority;P=
0.12forsuperiority)bythe intentiontotreatanalysis.Therateof ischemicstrokewassimilar






per year, P=0.44), as was any major bleeding event (3.6% vs. 3.45% per year, P=0.576).
Intracranialhemorrhageoccurredlessfrequentlywithrivaroxabanthanwithwarfarin(0.49%vs
0.74% per year; P=0.019). In general, ROCKETAF showed that rivaroxaban was noninferior





embolism prevention in patients with nonvalvular AF.A total of 18,201 patients were
randomizedtoeitherapixabanatadoseof5mgtwicedaily(bid)(dosereducedto2.5mgbid
with2ofthefollowingcriteria:age80years,bodyweight60kg,orserumcreatinine1.5






This impressive 21% reduction in the primary endpoint was largely driven by a reduction in




bleedingeventswere lower in the apixaban (2.13% vs. 3.09%per year,P<0.001), particularly
intracranial hemorrhages (0.33% vs. 0.80% per year, P<0.001). Apixabanwas also associated
withalowertotalmortalityrate(3.52%vs.3.94%peryear,P=0.047).Thebenefitofapixaban






or systemic embolismprevention in patientswith nonvalvular AF. A total of 21,105 patients
wereblindlyrandomizedto2dosesofedoxaban,60or30mgod,ortodoseadjustedwarfarin
(INR2.03.0).Forpatientsineitheredoxabangroup,thedosewashalvedifanyofthefollowing
characteristics were present at the time of randomization or during the study: estimated
creatinineclearance rateof30–50ml/min,abodyweight<60kg,or theconcomitantuseof
verapamilorquinidine(potentPgpinhibitors).PatientshadnonvalvularAFand2riskfactors




strokeor systemic embolism (1.18%vs. 1.50%per year,P<0.001 for noninferiority) andwas
superiorwith respect to theprimary safety outcomeofmajor bleeding (2.75% vs. 3.43%per
14 
  
year, P<0.001), particularly intracranial hemorrhages (0.39% vs. 0.85% per year, P<0.001).
Ischemic stroke was similar between the edoxaban and warfarin (1.25% vs. 1.25% per year,
P=0.97),andhemorrhagicstrokeoccurredlessfrequentlyintheedoxabangroup(0.26%vs.0.47%
per year, P<0.001). Lowdose (30mg od) edoxaban was also noninferior to warfarin for the
primary efficacy outcome (1.61% vs. 1.50% per year, P=0.005 for noninferiority) and was
superiorwith respect to theprimary safety outcomeofmajor bleeding (1.61% vs. 3.43%per
year, P<0.001), particularly intracranial hemorrhage (0.26% vs. 0.85% per year, P<0.001).
Ischemicstrokewasmorecommonintheedoxabangroup(1.77%vs.1.42%peryear,P<0.001).
Bycontrast,hemorrhagicstrokeoccurred less frequentlywithedoxaban(0.16%vs.0.47%per





bothedoxaban regimens thanwithwarfarin: 8.11%withwarfarin comparedwith7.26%with
highdoseedoxaban(P=0.003)and6.79%withlowdoseedoxaban(P<0.001).Insummary,both
oncedailydosesofedoxabanintheENGAGEAFTIMI48studywerenoninferiortowarfarinfor







differed in a numberof important respects. ROCKETAF,ARISTOTLE, and ENGAGEAFTIMI 48
wereblinded inbotharms,but inRELY,warfarin therapywasopenlabel. InROCKETAF, the
mean CHADS2 score was higher than those in the other three studies, leading to a higher




trials, primary analyses were performed in the intentiontotreat (ITT) population.  In
ROCKETAF,thiswasdoneasaperprotocolanalysisandsafetywasasontreatmentanalysis.
All four drugswere confirmed to benoninferior compared towarfarin. Therewas a general
trendinfavourofstudydrugs,butthelevelofsignificanceforsuperioritywasreachedonlyfor
apixabananddabigatran150mgbidbutnotforrivaroxabanandedoxabanintheITTanalysis.
Apart for dabigatran 150 mg bid, no study drug showed significantly better ischemic stroke




and intracranial hemorrhage. This represents a clear advantage of all four new drugs over
warfarin. Interestingly,theRELYstudy initiallyraisedaconcernaboutanumerical increase in




new appearance of pathological electrocardiographic Qwaves, did not show significant
differences between dabigatran and warfarin. The ARISTOTLE, ENGAGE AFTIMI 48,and
ROCKETAFstudiesdidnotcorroborateanincreaseinmyocardialinfarctionswiththesedrugs.








diagnosed nonanticoagulated AF patients who would do well on VKA achieving a high TTR,
especiallygivencostsoftheNOACsandgiventhatthebenefitsofNOACsoverVKAsmaybeonly
marginal in those with high TTRs.  An ESC position paper5 recommends use of the new
SAMeTT2R2score
9toaiddecisionmakingby identifyingthoseAFpatients likelytodowellon
warfarin (SAMeTT2R2 score 01) or those more likely to have poor anticoagulation control
(SAMeTT2R2score>2).ThosepatientswithaSAMeTT2R2score>2wouldprobablybebetteroff








PatientswithAFandrenal impairmentareathigh riskof stroke/thromboembolism,bleeding,
myocardial infarctionanddeath.23,24,25,26Nonetheless, thenetclinicalbenefit seemsto favour
use of oral anticoagulation, rather than no anticoagulation. Given the age and comorbidities
associatedwith AF, the presence of normal renal function or evenmild renal impairment at
baselinedoesnotprecludesomepatientsdeterioratingtosevererenalimpairment.27

Renal impairment might influence the balance between the safety and efficacy of NOACs





were 2.09%, 3.33%, and 5.44%, respectively.28Thus, exposure to dabigatran is increased by
renal impairment, and this correlates with the severity of renal dysfunction. Despite a dose
reduction,drugaccumulationandoverdosewereinitiallyreportedinelderlypatientswithalow
body weight and moderate renal insufficiency, which led to severe and fatal bleeding
complications.29In thosewithmoderate renal impairment, the lowerdoseofdabigatran (110
mg) should be used with regular monitoring of renal function.28,30A RELY subanalysis31has
demonstrated that theefficacyofbothdosagesofdabigatranwasconsistentwith theoverall





Theexcretionof rivaroxabanandapixaban isonlypartlydependentupon renal function,and
the riskof drug accumulation inpatientswith renal insufficiency is lower than thatobserved
withdabigatran (Figure1).For rivaroxaban, theevent ratewas2.06%foraCrCl80mL/min,
2.77%foraCrCl50–79mL/min,and3.37%forCrCl<50mL/min.16Forapixaban,theeventrate
was 1.5%, 2.5%, and 3.2% for normal renal function,mild impairment, andmoderatesevere
impairment, respectively.17 Both drugs can be administered at fixed doses in patients with
moderate renal impairment, and the currentprescribing label forbothdrugsallows itsuse if
creatinineclearanceis15mls/min.Forapixaban,arecentanalysisclearlyshowsthesafetyof





















patientswithAF (aged>75–80years)areoftendeniedwarfarinowing to theperceptionofa
substantially increasedbleeding risk in thepresenceofmultiplecomorbidities, impairedrenal




TheNOACshavemanybenefitsoverwarfarin forstrokeprevention inpatientswithAF in the
elderly. Treatment decisions also require an assessment of the practical considerations
associatedwiththesetreatments, includingtheneedfordoseadjustment inspecificpatients,








thrombotic events and bleeding risewith advancing age. For instance, patients aged over 75
years represented 43.1%, 31.2%, 40.2%, and 40.1% in the ROCKETAF, ARISTOTLE, ENGAGE
AFTIMI48,andRELYstudies,respectively.InROCKETAF,theefficacyandsafetyofrivaroxaban
appearstobeconsistentacrossagecategories.Inthevarioustrialswithrivaroxaban,apixaban
and edoxaban, no interaction with age was reported for the efficacy outcome and the





The ageadjusted prevalence of AF may be lower among Asians than among Caucasians.33
However,theprevalenceandincidenceofarterialthromboembolismmaydifferfromthoseof
European and American countries.38Specifically, Asian patients have a fivetosixfold higher
stroke risk than Caucasians, but anticoagulation therapy is not commonly given to Asian
patients with nonvalvular AF, probably because of the (perceived) risk of critical bleeding,
whichmight be higher in Asian patients. Indeed,warfarinrelated intracranial hemorrhage in
Asianpatientswasreportedtobe1.75per100patientyears,whichissignificantlyhigherthan
thatinCaucasians(0.34per100patientyears).39Thisisfurthercomplicatedbythedifficultyof





Moreover, inAsians, the riskof strokeandsystemicembolism forwarfarinanticoagulatedAF
patientsappearstobehighercomparedtoNonAsians,thoughAsianshadsimilarmeanCHADS2
scores.41Indeed, in theRELYAsiasubanalysis42,although themeanCHADS2scorewas2.2 in





meanCHADS2 scorewas2.1 inAsian countries (2.1 innonEastAsians), the incidence rateof
stroke and systemic embolismwas higher in Asians compared to NonAsians (3.39%/year vs
1.38%/year).Also,inthesetrials,theTTRwasgenerallylowerinAsianscomparedtononAsians
(RELY;56.5%inAsiansvs68.9%inNonAsians,ROCKETAF;52.4%vs55.2%,ARISTOTLE;60%vs
67%). These datawould suggest that trial investigators in Asia tended to keep an INR in the





Asians (the Asian subanalysis of edoxaban are awaited). The Asian subgroup analysis of the
RELY trial demonstrated superiority of dabigatran 150 mg bid over warfarin in reducing







of the ARISTOTLE trial43, apixaban had consistent benefits when comparedwithwarfarin for
strokeorsystemicembolisminEastAsianandnonEastAsianpatients.Theannualriskofmajor
bleedingfromapixabanwas2.02%forAsiansand2.15%fornonAsians.Therateofstrokeand




TheuseofNOACs inpatientswithAF inAsiaprovidesanopportunity for improvedqualityof
care, since the rate of both thromboembolism and bleeding risk associatedwithNOACswas




Themanagement of antiplatelet and anticoagulant therapy is challenging in patientswithAF







therapy together with an anticoagulant “triple therapy.”45,46A subanalysis of the RELY trial
showedan increasedriskofbleedingandthromboemboliceventsassociatedwithantiplatelet
therapy compared with no antiplatelet therapy and consistent treatment effects when
compared with warfarin, regardless of aspirin use.47 Both the ATLAS ACS 2TIMI 5148 and
APPRAISE249trials confirmed a dosedependent increase inmajor bleeding events, including
intracranial bleeding, with rivaroxaban and apixaban when they were combined with dual
antiplatelettherapy(DAPT).

In the ATLAS ACS 2TIMI 51, lowdose (2.5 mg bid) rivaroxaban was associated with a
significantly lower composite of cardiovascular death, myocardial infarction, or stroke (the
primary efficacy endpoint), compared to placebo.  Of note, the doseswere 2.5 or 5mg bid,
whichcorrespondtoonefourthandonehalf,respectively,ofthedosetestedinAFpatients.16In
APPRAISE2,however,theprimarysafetyoutcomeofmajorbleedingoccurredmoreoftenwith
apixaban thanwith theplacebo.Apixabanwasassociatedwithmore intracranialhemorrhage
and with a numerical increase in fatal bleeding. Consequently, the trial was terminated
prematurely before completing enrollment of the planned patients considering the overall
efficacy/safetybalance.









Patient’s preferences for OAC therapy should be an integral part of the treatment
decisionmakingprocess,50asadvocatedbycurrentclinicalguidelines.22Toenablepatients to
make informed choices about whether or not to initiate OAC and to allow them to choose
betweentheavailableOACdrugsrequiresthepatienttobeappropriatelyeducatedabouttheir
own individual risk of stroke (hence the need for OAC) and their risk of major bleeding
associatedwith the differentOACs. The responsibility for educatingAF patients and allowing
them to voice their preferences forOAC treatment lieswith the treating clinician.51A recent
studybyLaHayeandcolleagues52usedaniPadtopresentpatientswiththeir individualriskof
stroke(usingCHA2DS2VASc)andbleedingwithtreatment,usingavarietyofdifferentformats
and elicited their preferences for antithrombotic therapy. This study corroborates previous
research50whichreportsthatpatientsaremoreconcernedabouttheriskofstrokethantherisk
ofbleeding;patientswerepreparedtosuffer4.4majorbleedsinordertopreventonestroke.52
Involving patients’ in discussions about treatment options and eliciting their preferences
providesclinicianswiththeopportunitytoeducatepatientsaboutAFandtherisksandbenefits







Thisoverviewhas several limitations.First,eachphase III trialexamineddifferentNOACsand
therewasimportantheterogeneityregardingstudydesignsandincludedpopulations.Second,
patients takingwarfarin in reallifeclinicalpracticeare less likely tobe ina therapeutic range
than those in controlled studies.Therefore, further insights into theappropriateuseof these
agents will become apparent when they are used in ‘realworld’ clinical settings, and some
initialdatafrompostmarketingstudiesdosuggestthatthesedrugsappearsafecomparedto
warfarin when used in newly diagnosed anticoagulation naïve patients.53,54 Some reports
suggest need for caution amongst ‘switchers’ from warfarin to NOACs, and a high rate of
bleedingandthromboembolismwasobserved.55  It isworthemphasizingthatthesedrugsare
powerful anticoagulants that offer efficacy and safety compared towarfarin if used correctly
accordingtoguidelinesand/orprescribingrecommendations.56

The introduction of 4 new NOAC alternatives for anticoagulation represents a major step
forwardinimprovingoutcomesandqualityoflife.ComparedwithVKAs,thesenewalternatives
have important advantages, such as lower risk of intracranial bleeding, no clear interactions
withfood, favorable pharmacokinetic profiles, and no need for routine monitoring. Indeed,
theseneworalanticoagulantswillbepreferredalternativestoVKAsformanypatientswithAF
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Figure1Majorbleedingrate(%/year)accordingtocreatinineclearance(CCr)
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